down arrow

Jasper Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Finance
  • ISIN: US4718712023
USD
1.86
0.28 (17.72%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.591.89

52 Week

1.4023.89
Valuation
Technical
Day's Volume

CASH

1.97 M

Shareholding (Mar 2025)

FII

21.00%

Held by 30 FIIs

DII

43.29%

Held by 20 DIIs

Promoter

18.01%

How big is Jasper Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Jasper Therapeutics, Inc. has a market capitalization of 81.27 million, with net sales of 0.00 million and a net profit of -78.78 million over the latest four quarters. The company's shareholder's funds are 61.67 million, and total assets are 79.90 million as of Dec 24.

Market Cap: As of Jun 18, Jasper Therapeutics, Inc. has a market capitalization of 81.27 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Jasper Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -78.78 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 61.67 million, while total assets were reported at 79.90 million.

Read More

What does Jasper Therapeutics, Inc. do?

22-Jun-2025

Jasper Therapeutics, Inc. is a blank check company focused on acquiring opportunities in the healthcare sector, currently classified as a micro-cap with a market cap of $81.27 million and a recent net profit loss of $21 million.

Overview:<BR>Jasper Therapeutics, Inc. is a blank check company focused on pursuing acquisition opportunities in the healthcare or healthcare-related industries, operating within the finance sector and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -21 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 81.27 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.09<BR>Return on Equity: -186.54%<BR>Price to Book: 1.92<BR><BR>Contact Details:<BR>Address: 1177 Avenue of the Americas Fl 40, NEW YORK NY: 10036-2714<BR>Tel: 1 212 8231900<BR>Fax: 1 302 6365454

Read More

Is Jasper Therapeutics, Inc. technically bullish or bearish?

25-Jun-2025

As of June 9, 2025, the market trend is mildly bearish, indicated by daily moving averages and monthly Bollinger Bands, despite some mixed signals from weekly indicators and a notable decline in stock performance compared to the S&P 500.

As of 9 June 2025, the technical trend has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven primarily by the daily moving averages indicating a bearish sentiment and the monthly Bollinger Bands also reflecting a bearish trend. While the weekly MACD and KST show mildly bullish signals, they are overshadowed by the overall bearish indicators in the monthly timeframe. The Dow Theory presents a mixed view with a mildly bearish weekly stance and a mildly bullish monthly stance, adding to the complexity of the current situation. Overall, the strength of the bearish trend is supported by the significant decline in stock performance compared to the S&P 500 over various time frames, particularly the year-to-date and three-year returns.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Finance

stock-summary
Market cap

USD 43 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.09

stock-summary
Return on Equity

-386.97%

stock-summary
Price to Book

1.83

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-27 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-31.62%
0%
-31.62%
6 Months
-68.47%
0%
-68.47%
1 Year
-92.13%
0%
-92.13%
2 Years
-70.23%
0%
-70.23%
3 Years
204.92%
0%
204.92%
4 Years
-97.65%
0%
-97.65%
5 Years
-98.12%
0%
-98.12%

Jasper Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-396.97%
EBIT to Interest (avg)
-51.62
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.09
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.14
EV to EBIT
-0.52
EV to EBITDA
-0.53
EV to Capital Employed
-9.18
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-186.54%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 20 Schemes (17.7%)

Foreign Institutions

Held by 30 Foreign Institutions (21.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -82.88% vs 9.32% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.80",
          "val2": "-15.70",
          "chgp": "-70.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-26.70",
          "val2": "-14.60",
          "chgp": "-82.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -10.54% vs -71.09% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-76.40",
          "val2": "-69.40",
          "chgp": "-10.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.60",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-71.30",
          "val2": "-64.50",
          "chgp": "-10.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-26.80
-15.70
-70.70%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-26.70
-14.60
-82.88%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -82.88% vs 9.32% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-76.40
-69.40
-10.09%
Interest
0.00
0.00
Exceptional Items
0.00
-0.60
100.00%
Consolidate Net Profit
-71.30
-64.50
-10.54%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -10.54% vs -71.09% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Jasper Therapeutics, Inc. stock-summary
stock-summary
Jasper Therapeutics, Inc.
Finance
Amplitude Healthcare Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target, and is focused on pursuing an acquisition opportunity in any business, industry sector or geographical location. It intends to acquire a business focused on the healthcare or healthcare related industries in the United States and Europe. The Company is not engaged in any business operations and has not generated any revenue.
Company Coordinates stock-summary
Company Details
1177 Avenue of the Americas Fl 40 , NEW YORK NY : 10036-2714
stock-summary
Tel: 1 212 8231900
stock-summary
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."